14.07.2023 – 11:08
PHARMA FACTS
Munich (ots)
There are still 6.5 years: by then, according to the goals of the United Nations, HIV/AIDS should be over. That would be possible. That shows a new report by the organization UNAIDS. And Martin Flörkemeier from Gilead Sciences, a leading developer of HIV drugs, also knows that this can work, because all the tools are there. A conversation about what still needs to be done in Germany:
When reprinting, please state the source: pharma-fakten.de
Please send specimen copies to [email protected].
Further articles, news and graphics on the subject of HIV/AIDS can be found here:
“Sexual health counseling for trans and non-binary people should be valued”
“Sexual health and HIV/STI in trans and non-binary communities” – this is the title of a joint study by German Aidshilfe and the Robert Koch Institute. We spoke to the project manager Chris Spurgat from the German Aidshilfe about the results and conclusions – and about what needs to change in order to close blatant gaps in care.
https://ots.de/Xnh1Ul
Containing HIV: Good for health, society and the economy
Low- and middle-income countries would need around US$29 billion a year to end HIV/AIDS as a public health threat by 2030. UNAIDS, the United Nations Joint Program, appreciates that. An analysis across 13 African countries now shows that such investments are worthwhile in three ways. Because they would not only save millions of lives – they would have positive consequences for the health of the population, society and the economy.
https://ots.de/hXMKT8
HIV-PrEP: Of large gaps and white patches
Pre-exposure prophylaxis – a bulky word with a resounding effect: PrEP plays an important role in the plans of the World Health Organization (WHO) to contain HIV and AIDS by 2030. It consists of an antiretroviral medicine that can protect HIV-negative people from infection. But access to PrEP in Europe is unnecessarily difficult. Germany’s PrEP map also has many white spots.
https://ots.de/1f1pvI
PHARMA FACTS – An initiative by drug manufacturers in Germany
PHARMA FACTS is an initiative of Pharma Facts eV, in which 16 companies from the pharmaceutical industry are organized. The core of the initiative is the online platform www.pharma-fakten.de, on which an independent editorial team is continuously working. Pharma Facts has been reporting regularly on health topics since 2014. The focus is on the research and development of new drugs for a wide variety of indications as well as health policy and economic backgrounds.
Press contact:
Editorial Pharma Facts
www.pharma-fakten.de
E-Mail: [email protected]
Original content from: PHARMA FAKTEN, transmitted by news aktuell